我的动态里满是关于新型癌症药物达拉西尼布（daraxonrasib）的消息，有些人甚至称其为“奇迹药物”。

在癌症研究上花费了超过500亿美元的资金，而这似乎是过去5年主流癌症研究所能提供的最好成果。

达拉西尼布（Daraxonrasib）关键要点：

- 费用为每月40,000美元，或每年480,000美元- 在胰腺癌中严重副作用发生率为43.6%- 在肺癌中严重副作用发生率为54%，包括2.9%的死亡率- 在胰腺癌中总生存期（OS）获益约为7个月

我不仅仅在关注伊维菌素、美苯达唑和芬苯达唑。我希望癌症患者有更多选择！

我曾帮助开发了Lutathera和Pluvicto，如今诺华制药每年从中获利28亿美元，而大制药公司的资产却试图在我癌症研究成果被窃取并转移到不列颠哥伦比亚省后摧毁我的医学生涯。

我一直对ANKTIVA持开放态度，并对其潜力感到好奇。斯科特·亚当斯（Scott Adams）只是一个不适合使用它的错误患者。

但主流癌症研究并没有产出任何令人印象深刻的东西，它必须拥抱其他探索途径，比如药物再利用。🙏

主流肿瘤学必须迅速适应。

My feed is filled with new cancer drug daraxonrasib which is being hailed by some as a "miracle drug".

Over $50 billion in Cancer Research money spent, and this seems to be the best that mainstream Cancer Research has to offer in the past 5 years.

Daraxonrasib key points:

- cost is $40,000/month or $480,000/year- 43.6% severe side effect rate in pancreatic cancer- 54% severe side effect rate including 2.9% deaths in lung cancer- OS benefit of about 7 months in pancreatic ca

I'm not looking at just Ivermectin, Mebendazole and Fenbendazole. I want cancer patients to have options!

I helped develop Lutathera and Pluvicto and now Novartis makes $2.8 billion on them annually while Big Pharma assets tried to destroy my medical career after my Cancer Research was stolen and moved to BC.

I've remained open to ANKTIVA and curious about its potential. Scott Adams was simply the wrong patient to give it to.

But mainstream Cancer Research is not producing anything impressive and it has to embrace other avenues of inquiry, like repurposed drugs. 🙏

Mainstream Oncology has to adapt quickly.